Consultas previa cita:
 
Zona 10 
Lunes a Jueves
8:00 - 18:00 horas
 
Viernes
8:00 - 13:00 horas

Dr. Fernando Stuardo Wyss Quintana Md, Phd, FSIAC, ESHM, ESCM, LASHM, RAG ISH, FAHA.

Medicina Interna - Cardiología 

  1. Elected President of the Interamerican Society of Cardiology

  2. Past President of the Central American and Caribbean Society of Hypertension and Cardiovascular Prevention - SCCH

  3. Member of the Latin-American Society of Hypertension - LASH

  4. Full Member of the European Hypertension Society

  5. Full Member of Latin-American Society of Interventional Cardiology

  6. Member of the European Society of Cardiology

  7. Fellow of the Interamerican Society of Cardiology - FIASC

  8. Honorary Fellow of American Heart Asociation - FAHA

  9. Regional Advisory Group of International Society of Hypertension

  10. Honorary Member of the Dominican Society of Hypertension and Atherosclerosis

  11. Honorary Member of the Colombian Society of Cardiology

  12. Speaker in the World Heart Federation - World Congress of Cardiology, Australia 2014, Mexico 2016 and Dubai 2018

  13. Abstracts reviewer for World Heart Federation - World Congress of Cardiology, Australia 2014, Mexico 2016 and Dubai 2018.

  14. Member of the Scientific Committee of AHA 2018.

  15. Member of the Review Committee of Abstracts ESH 2018

  16. Speaker

    1. American Heart Asociation

    2. American College of Cardiology

    3. World Heart Federation

    4. European Society of Hypertension

    5. Interamerican Society of Cardiology

    6. Latin-American Society of Hypertension

    7. International Society of Hypertension

    8. Central America Society of Cardiology

    9. South American Society of Cardiology

  17. speaker in different countries

    1. United States

    2. México

    3. Central América (Guatemala, El Salvador, Honduras, Nicaragua, Costa Rica and Panama)

    4. Caribbean (Puerto Rico and Dominican Republic)

    5. English Caribbean

    6. South America (Colombia, Perú, Argentina and Brasil)

    7. Europe (Greece, Italy and Spain)

    8. Korea

    9. Australia

    10. China

    11. Dubai

  18. Principal Investigator and Member of the Executive Committee of the CANTOS study "The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study"

 

Publications and Papers

Researcher, Principal Investigator, Sub investigator, Collaborator, First Author

  1. Guidelines on the management of arterial hypertension and related comorbidities in Latin America. Barbosa E; Lopez Jaramillo P; Zanchetti A; Coca A; Wyss F; et al……. Task Force of the Latin American Society of Hypertension Journal of Hypertension 2017, 35:1529–1545

  2. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group. Lancet. 2017 Nov 13. pii: S0140-6736(17)32814-3. doi: 10.1016/S0140-6736(17)32814-3. [Epub ahead of print]}

  3. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ; CANTOS Trial Group. Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27

  4. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.

  5. Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project. Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, Hennis A, Asma S, Angell S; por la Red de Prevención y Tratamiento Estandarizado de la Hipertensión Arterial. Rev Panam Salud Publica. 2017 Jun 8;41:1. Spanish. 

  6. Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project. Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, Hennis A, Asma S, Angell S; Standardized Hypertension Treatment and Prevention Network. J Clin Hypertens (Greenwich). 2016 Dec;18(12):1284-1294. doi: 10.1111/jch.12861. Epub 2016 Jul 4.

  7. Atherogenic Dyslipidemia in Latin America: Prevalence, causes and treatment: Expert's position paper made by The Latin American Academy for the Study of Lipids (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the South American Society of Cardiology (SSC), the Pan-American College of Endothelium (PACE), and the International Atherosclerosis Society (IAS). Ponte-Negretti CIIsea-Perez JELorenzatti AJLopez-Jaramillo PWyss-Q FSPintó XLanas FMedina JMachado-H LTAcevedo MVarleta PBryce ACarrera CPeñaherrera CEGómez-M JRLozada AMerchan-V APiskorz DMorales EPaniagua MMedina-Palomin FVillar-M RACobos LGómez-Alvares EAlonso RColan JChirinos JLara JUllauri VArocha I. Int J Cardiol. 2017 Sep 15; 243: 516 - 522. doi: 10.1016/j.ijcard.2017.05.059. Epub 2017 May 18.

  8. Atherogenic dyslipidemia in Latin America: prevalence, causes and treatment. Consensus. Ponte-Negretti CI, Isea-Pérez J, Lanas F, Medina J, Gómez-Mancebo J, Morales E, Acevedo M, Pirskorz D, Machado L, Lozada A, Bryce A, Lorenzatti A, Carrera C, López-Jaramillo P, Pinto X, Wyss-Quintana FS. Rev Mex Cardiol 2017; 28 (2)

  9. Dislipidemia Aterogenica en Latinoamerica, Prevalencia, Cuasas y Tratamiento. Ponte-Negretti CI, Isea-Pérez J, Lanas F, Medina J, Gómez-Mancebo J, Morales E, Acevedo M, Pirskorz D, Machado L, Lozada A, Bryce A, Lorenzatti A, Carrera C, López-Jaramillo P, Pinto X, Wyss-Quintana FS. Avances en Cardiologia de Venezuela 2017: 37 (3): 161- 167

  10. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP - CHAGAS Trial. Morillo CA, Waskin H, Sosa-Estani S, Del Carmen Bangher M, Cuneo C, Milesi R, Mallagray M, Apt W, Beloscar J, Gascon J, Molina I, Echeverria LE, Colombo H, Perez-Molina JA, Wyss F, Meeks B, Bonilla LR, Gao P, Wei B, McCarthy M, Yusuf S; STOP-CHAGAS Investigators. J Am Coll Cardiol. 2017 Feb 28;69(8):939-947. doi: 10.1016/j.jacc.2016.12.023.

  11. SSA 04-4. CURRENT STATUS IN MANAGEMENT OF HYPERTENSION IN LATIN AMERICA. Fernando Wyss. Journal of Hypertension: September 2016 - Volume 34 - Issue - p e7–e8

  12. Improved Blood Pressure Control to Reduce Cardiovascular Disease Morbidity and Mortality: The Standardized Hypertension Treatment and Prevention Project. Patel P, Ordunez P, DiPette D, Escobar MC, Hassell T, Wyss F, Hennis A, Asma S, Angell S; Standardized Hypertension Treatment and Prevention Network. J Clin Hypertens (Greenwich). 2016 Dec;18(12):1284-1294. doi: 10.1111/jch.12861. Epub 2016 Jul 4.

  13. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

  14. Differences between the 2013 and 2014 hypertension guidelines.: Position of the Central American and Caribbean Society for Hypertension and Cardiovascular Prevention. Morales-Salinas A, Wyss F, Coca A, Ramírez AJ, Valdez O, Valerio LF. Rev Panam Salud Publica. 2015 Mar;37(3):172-8. Spanish. 

  15. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators. Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. Epub 2015 Feb 12.

  16. Guidelines for managing high blood pressure. Morales-Salinas A, Coca A, Wyss FS. JAMA. 2014 Jul 16;312(3):293-4. doi: 10.1001/jama.2014.6590. No abstract available. 

  17. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. Bobrie G; I-ADD Study Investigators. Clin Ther. 2012 Aug;34(8):1720-34. e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30.

  18. Management of acute coronary syndromes in developing countries: acute coronary events-a multinational survey of current management strategies. ACCESS Investigators. Am Heart J. 2011 Nov;162(5):852-859.e22. doi: 10.1016/j.ahj.2011.07.029.

  19. Aliskiren and the Channel Calcium Blocker Amlodipne as an initial treatment strategy for Hypertension control (ACCELERATE). randomized, parallel group trial. The Lancet 2011; 377. 312 - 320.

Dr. Marcos Alberto Ramirez Granados 

Medicina Interna - Cardiología

 

Medico y cirujano, egresado de la Universidad de San Carlos de Guatemala 

 

Medicina interna, Hospital Militar de Guatemala 

 

Cardiología clínica, egresado de la Universidad del Ejercito y Fuerza Aérea y Hospital Central Militar de México 

Medico Adscrito y Jefe de la Unidad de Cardiologia del Hospital Militar de Guatemala 

Consultas previa cita:
 
Zona 10 
Lunes a Viernes
15:00 - 18:00 Horas
Sábados
8:00 - 12:00 Horas

Dr. José Virgilio Linares Ávila

Medicina Interna - Cardiología

 

Medico y cirujano, egresado de la Universidad de San Carlos de Guatemala

 

Medicina interna, Hospital General San Juan de Dios, Guatemala

 

Cardiología clínica, egresado de la Universidad Autónoma de San Luis Potosí, México

 

Certificado por el Consejo Mexicano de Cardiología

 

Fellow in training del American College of Cardiology

AL MOMENTO EN ESPAÑA DURANTE DOS AÑOS